Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 9/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.39 |
| ▸ | TCF7L2 | Q9NQB0 | 3/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874661 | 0.95 | CTNNB1 (0.44) | GPR139DGAT1MEN1KMT2AATM | |
| SCHEMBL875423 | 0.93 | GPR139 (0.45) | GPR139DGAT1MEN1KMT2AHTT | |
| SCHEMBL875589 | 0.89 | GPR139 (0.49) | GPR139DGAT1HTTRAB9ANPC1 | |
| SCHEMBL878096 | 0.88 | GPR139 (0.45) | GPR139DGAT1MEN1KMT2AATM | |
| SCHEMBL878120 | 0.88 | MAPT (0.46) | GPR139DGAT1HTTRAB9ANPC1 | |
| SCHEMBL874668 | 0.87 | GPR139 (0.49) | GPR139KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL874987 | 0.86 | DGAT1 (0.49) | GPR139DGAT1MEN1KMT2AHTT | |
| SCHEMBL878124 | 0.85 | GPR139 (0.44) | GPR139DGAT1MEN1KMT2AHTT | |
| SCHEMBL878139 | 0.83 | GPR139 (0.45) | GPR139MEN1KMT2AATMRAB9A | |
| SCHEMBL15732962 | 0.83 | GPR139 (0.49) | GPR139KMT2AHTTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2014-05-29 | — | — | US | claimed |
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
| EP-2619185-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038942-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP12, MMP10 | GPR139 2694/4885DGAT1 888/4885MEN1 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.